Drug targeting of dysregulated transcription in Huntington's disease

Progress in Neurobiology

Volumn 83, Issue 4, 2007, Pages 249-259

  Kazantsev, Aleksey G ^a   Hersch, Steven M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Huntington's disease; Mutant huntingtin; Neuroprotection; Small molecule; Transcription factor(s); Transcriptional dysregulation

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; HISTONE; HISTONE DEACETYLASE; HUNTINGTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; SIRTUIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1;

ACETYLATION; HUMAN; HUNTINGTON CHOREA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW;

DRUG DESIGN; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 35348880250     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2007.02.005     Document Type: Review

References (64)

1. Augood S.J., Faull R.L., and Emson P.C. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol. 42 (1997) 215-221
2. Augood S.J., Faull R.L., Love D.R., and Emson P.C. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience 72 (1996) 1023-1036
3. Bae B.I., Xu H., Igarashi S., Fujimuro M., Agrawal N., Taya Y., Hayward S.D., Moran T.H., Montell C., Ross C.A., Snyder S.H., and Sawa A. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47 (2005) 29-41
4. Bates E.A., Victor M., Jones A.K., Shi Y., and Hart A.C. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J. Neurosci. 26 (2006) 2830-2838
5. Baur J.A., and Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug. Discov. 5 (2006) 493-506
6. Beal M.F., and Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 5 (2004) 373-384
7. Blander G., and Guarente L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73 (2004) 417-435
8. Borovecki F., Lovrecic L., Zhou J., Jeong H., Then F., Rosas H.D., Hersch S.M., Hogarth P., Bouzou B., Jensen R.V., and Krainc D. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 11023-11028
9. Borra M.T., Smith B.C., and Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280 (2005) 17187-17195
10. Cha J.H., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., Mangiarini L., Penney Jr. J.B., Davies S.W., Bates G.P., and Young A.B. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 354 (1999) 981-989
11. Chan E.Y., Luthi-Carter R., Strand A., Solano S.M., Hanson S.A., DeJohn M.M., Kooperberg C., Chase K.O., DiFiglia M., Young A.B., Leavitt B.R., Cha J.H., Aronin N., Hayden M.R., and Olson J.M. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum. Mol. Genet. 11 (2002) 1939-1951
12. Cong S.Y., Pepers B.A., Evert B.O., Rubinsztein D.C., Roos R.A., van Ommen G.J., and Dorsman J.C. Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. Mol. Cell Neurosci. 30 (2005) 560-571
13. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., and Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 (1997) 537-548
14. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., and Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 (1997) 1990-1993
15. Dumble M.L., Donehower L.A., and Lu X. Generation and characterization of p53 mutant mice. Methods Mol. Biol. 234 (2003) 29-49
16. Dunah A.W., Jeong H., Griffin A., Kim Y.M., Standaert D.G., Hersch S.M., Mouradian M.M., Young A.B., Tanese N., and Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296 (2002) 2238-2243
17. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., Smith K., Kowall N.W., Ratan R.R., Luthi-Carter R., and Hersch S.M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23 (2003) 9418-9427
18. Ferrante R.J., Ryu H., Kubilus J.K., D'Mello S., Sugars K.L., Lee J., Lu P., Smith K., Browne S., Beal M.F., Kristal B.S., Stavrovskaya I.G., Hewett S., Rubinsztein D.C., Langley B., and Ratan R.R. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J. Neurosci. 24 (2004) 10335-10342
19. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 14 (2000) 1021-1026
20. Guarente L., and Kenyon C. Genetic pathways that regulate ageing in model organisms. Nature 408 (2000) 255-262
21. Harper S.Q., Staber P.D., He X., Eliason S.L., Martins I.H., Mao Q., Yang L., Kotin R.M., Paulson H.L., and Davidson B.L. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 5820-5825
22. Hildmann C., Wegener D., Riester D., Hempel R., Schober A., Merana J., Giurato L., Guccione S., Nielsen T.K., Ficner R., and Schwienhorst A. Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. J. Biotechnol. 124 (2006) 258-270
23. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., Sathasivam K., Ghazi-Noori S., Mahal A., Lowden P.A., Steffan J.S., Marsh J.L., Thompson L.M., Lewis C.M., Marks P.A., and Bates G.P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 2041-2046
24. Igarashi S., Morita H., Bennett K.M., Tanaka Y., Engelender S., Peters M.F., Cooper J.K., Wood J.D., Sawa A., and Ross C.A. Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport 14 (2003) 565-568
25. Imai S., Armstrong C.M., Kaeberlein M., and Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403 (2000) 795-800
26. Iwata A., Riley B.E., Johnston J.A., and Kopito R.R. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J. Biol. Chem. 280 (2005) 40282-40292
27. Jiang H., Nucifora Jr. F.C., Ross C.A., and DeFranco D.B. Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum. Mol. Genet. 12 (2003) 1-12
28. Jiang H., Poirier M.A., Liang Y., Pei Z., Weiskittel C.E., Smith W.W., Defranco D.B., and Ross C.A. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol. Dis. 23 (2006) 543-551
29. Kaeberlein M., McVey M., and Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes. Dev. 13 (1999) 2570-2580
30. Kazantsev A., Preisinger E., Dranovsky A., Goldgaber D., and Housman D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 11404-11409
31. Kegel K.B., Meloni A.R., Yi Y., Kim Y.J., Doyle E., Cuiffo B.G., Sapp E., Wang Y., Qin Z.H., Chen J.D., Nevins J.R., Aronin N., and DiFiglia M. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 277 (2002) 7466-7476
32. Kennedy B.K., Gotta M., Sinclair D.A., Mills K., McNabb D.S., Murthy M., Pak S.M., Laroche T., Gasser S.M., and Guarente L. Redistribution of silencing proteins from telomeres to the nucleolus is associated with extension of life span in S. cerevisiae. Cell 89 (1997) 381-391
33. Khoshnan A., Ko J., Watkin E.E., Paige L.A., Reinhart P.H., and Patterson P.H. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J. Neurosci. 24 (2004) 7999-8008
34. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cadigan B.A., Warzecki L., Tagle D.A., Reddy P.H., Cepeda C., Calvert C.R., Jokel E.S., Klapstein G.J., Ariano M.A., Levine M.S., DiFiglia M., and Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J. Neurosci. 21 (2001) 9112-9123
35. Li S.H., Cheng A.L., Zhou H., Lam S., Rao M., Li H., and Li X.J. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell Biol. 22 (2002) 1277-1287
36. Luthi-Carter R., Hanson S.A., Strand A.D., Bergstrom D.A., Chun W., Peters N.L., Woods A.M., Chan E.Y., Kooperberg C., Krainc D., Young A.B., Tapscott S.J., and Olson J.M. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 11 (2002) 1911-1926
37. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.H., and Olson J.M. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9 (2000) 1259-1271
38. Luthi-Carter R., Strand A.D., Hanson S.A., Kooperberg C., Schilling G., La Spada A.R., Merry D.E., Young A.B., Ross C.A., Borchelt D.R., and Olson J.M. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet. 11 (2002) 1927-1937
39. Mantamadiotis T., Lemberger T., Bleckmann S.C., Kern H., Kretz O., Martin Villalba A., Tronche F., Kellendonk C., Gau D., Kapfhammer J., Otto C., Schmid W., and Schutz G. Disruption of CREB function in brain leads to neurodegeneration. Nat. Genet. 31 (2002) 47-54
40. Mattson M.P., Maudsley S., and Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 27 (2004) 589-594
41. Mee P.J., O'Brien C.M., Thomson H., van der Sar S., Lakics V., and Allsopp T.E. Embryonic stem cells as a source of differentiated neural cells for pharmacological screens. Methods Mol. Biol. 329 (2006) 353-369
42. North B.J., Marshall B.L., Borra M.T., Denu J.M., and Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell 11 (2003) 437-444
43. Nucifora Jr. F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L., Dawson T.M., and Ross C.A. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291 (2001) 2423-2428
44. Parker A.J., Arango M., Abderrahmane S., Lambert E., Tourette C., Catoire H., and Neri C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Med. Sci. (Paris) 21 (2005) 556-557
45. Qin Z.H., Wang Y., Nakai M., and Chase T.N. Nuclear factor-kappa B contributes to excitotoxin-induced apoptosis in rat striatum. Mol. Pharmacol. 53 (1998) 33-42
46. Qiu Z., Norflus F., Singh B., Swindell M.K., Buzescu R., Bejarano M., Chopra R., Zucker B., Benn C.L., DiRocco D.P., Cha J.H., Ferrante R.J., and Hersch S.M. Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J. Biol. Chem. 281 (2006) 16672-16680
47. Ryu H., Rosas H.D., Hersch S.M., and Ferrante R.J. The therapeutic role of creatine in Huntington's disease. Pharmacol. Ther. 108 (2005) 193-207
48. Sadri-Vakili G., Menon A.S., Farrell L.A., Keller-McGandy C.E., Cantuti-Castelvetri I., Standaert D.G., Augood S.J., Yohrling G.J., and Cha J.H. Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse. Eur. J. Neurosci. 23 (2006) 3171-3175
49. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G.P., Davies S.W., Lehrach H., and Wanker E.E. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90 (1997) 549-558
50. Sipione S., Rigamonti D., Valenza M., Zuccato C., Conti L., Pritchard J., Kooperberg C., Olson J.M., and Cattaneo E. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum. Mol. Genet. 11 (2002) 1953-1965
51. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., Kazantsev A., Schmidt E., Zhu Y.Z., Greenwald M., Kurokawa R., Housman D.E., Jackson G.R., Marsh J.L., and Thompson L.M. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413 (2001) 739-743
52. Steffan J.S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.Z., Gohler H., Wanker E.E., Bates G.P., Housman D.E., and Thompson L.M. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6763-6768
53. Takano H., and Gusella J.F. The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family transcription factor. BMC Neurosci. 3 (2002) 15
54. Tissenbaum H.A., and Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410 (2001) 227-230
55. Vaquero A., Scher M.B., Lee D.H., Sutton A., Cheng H.L., Alt F.W., Serrano L., Sternglanz R., and Reinberg D. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. 20 (2006) 1256-1261
56. Viswanathan M., Kim S.K., Berdichevsky A., and Guarente L. A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span. Dev. Cell 9 (2005) 605-615
57. Wang D.F., Helquist P., Wiech N.L., and Wiest O. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J. Med. Chem. 48 (2005) 6936-6947
58. Wang H., Lim P.J., Yin C., Rieckher M., Vogel B.E., and Monteiro M.J. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin. Hum. Mol. Genet. 15 (2006) 1025-1041
59. White J.K., Auerbach W., Duyao M.P., Vonsattel J.P., Gusella J.F., Joyner A.L., and MacDonald M.E. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet. 17 (1997) 404-410
60. Yu Z., Zhou D., Cheng G., and Mattson M.P. Neuroprotective role for the p50 subunit of NF-kappaB in an experimental model of Huntington's disease. J. Mol. Neurosci. 15 (2000) 31-44
61. Yu Z.X., Li S.H., Nguyen H.P., and Li X.J. Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum. Mol. Genet. 11 (2002) 905-914
62. Zhai W., Jeong H., Cui L., Krainc D., and Tjian R. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 123 (2005) 1241-1253
63. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., Timmusk T., Sipione S., and Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293 (2001) 493-498
64. Zuccato C., Tartari M., Crotti A., Goffredo D., Valenza M., Conti L., Cataudella T., Leavitt B.R., Hayden M.R., Timmusk T., Rigamonti D., and Cattaneo E. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35 (2003) 76-83